Skip to content
Publish & Distribute
Publishing Solutions
Distribution Solutions
Library Services
Subjects
Architecture and Design
Arts
Business and Economics
Chemistry
Classical and Ancient Near Eastern Studies
Computer Sciences
Cultural Studies
Engineering
General Interest
Geosciences
History
Industrial Chemistry
Jewish Studies
Law
Library and Information Science, Book Studies
Life Sciences
Linguistics and Semiotics
Literary Studies
Materials Sciences
Mathematics
Medicine
Music
Pharmacy
Philosophy
Physics
Social Sciences
Sports and Recreation
Theology and Religion
Publications
Journals
Books
Proceedings
Publishers
Journal Matcher
Blog
Contact
Search
English
English
Deutsch
Polski
Español
Français
Italiano
Cart
Home
Journals
Acta Pharmaceutica
Volume 72 (2022): Issue 3 (September 2022)
Open Access
AXL inhibitors selected by molecular docking: Option for reducing SARS-CoV-2 entry into cells
Octavio Galindo-Hernández
Octavio Galindo-Hernández
Facultad de Medicina Mexicali, Universidad Autónoma de Baja
California,
Search for this author on
Sciendo
|
Google Scholar
Galindo-Hernández, Octavio
and
José Luis Vique-Sánchez
José Luis Vique-Sánchez
Facultad de Medicina Mexicali, Universidad Autónoma de Baja
California,
Search for this author on
Sciendo
|
Google Scholar
Vique-Sánchez, José Luis
Apr 13, 2022
Acta Pharmaceutica
Volume 72 (2022): Issue 3 (September 2022)
About this article
Previous Article
Next Article
Abstract
References
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Download Cover
Published Online:
Apr 13, 2022
Page range:
329 - 343
Accepted:
Oct 18, 2021
DOI:
https://doi.org/10.2478/acph-2022-0024
Keywords
COVID-19
,
SARS-CoV-2
,
AXL ligand
,
molecular docking
,
NTD-S1
,
S protein
© 2022 Octavio Galindo-Hernández et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
